Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleArticle

DISPOSITION OF CLONIXIN [2-(3-CHLORO-o-TOLUIDINO) NICOTINIC ACID] IN HUMANS

B. Katchen, S. Buxbaum and J. Ning
Journal of Pharmacology and Experimental Therapeutics October 1973, 187 (1) 152-157;
B. Katchen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S. Buxbaum
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. Ning
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

These studies were designed to gain insight into the pharmacodynamics and pharmacokinetics of clonixin in humans and to determine the degree of similarity of human and animal excretion and urine metabolite patterns. Clonixin is rapidly absorbed and excreted by humans. Peak plasma levels are attained in one hour; in 24 hours, 62% of an oral 500-mg dose is excreted in the urine and less than 1% in the feces. In 120 hours 86% is excreted in urine and feces. Clonixin is the major compound found in plasma up to six hours after drug administration, but clonixin and 4'-OH clonixin—and to a lesser extent, 5-OH clonixin and the 2'-CH2OH metabolite—are the major compounds excreted in 0- to 24-hour urine. Clonixin plasma levels fit an open one-compartment model (ka = 1.35, ke = 0.48 and = Vd 0.1l2 1/kg), and are not measurable 16 hours after drug administration. Human and rhesus monkey urine excretion patterns are quantitatively similar and the urine metabolite patterns are qualitatively similar. The similarity of these patterns suggests that clonixin activity and toxicity shisould be similar in both species.

Footnotes

    • Received April 20, 1973.
    • Accepted June 1, 1973.
  • © 1973 by The Williams & Wilkins Company

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics
Vol. 187, Issue 1
1 Oct 1973
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
DISPOSITION OF CLONIXIN [2-(3-CHLORO-o-TOLUIDINO) NICOTINIC ACID] IN HUMANS
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

DISPOSITION OF CLONIXIN [2-(3-CHLORO-o-TOLUIDINO) NICOTINIC ACID] IN HUMANS

B. Katchen, S. Buxbaum and J. Ning
Journal of Pharmacology and Experimental Therapeutics October 1, 1973, 187 (1) 152-157;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

DISPOSITION OF CLONIXIN [2-(3-CHLORO-o-TOLUIDINO) NICOTINIC ACID] IN HUMANS

B. Katchen, S. Buxbaum and J. Ning
Journal of Pharmacology and Experimental Therapeutics October 1, 1973, 187 (1) 152-157;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • PST3093 Stimulates SERCA2a and Improves Cardiac Function
  • CRV431 Decreases Liver Fibrosis and Tumor Development
  • Toxicity, Biological Activity, and Pharmacokinetics of TXU (Anti-CD7)-Pokeweed Antiviral Protein in Chimpanzees and Adult Patients Infected with Human Immunodeficiency Virus
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics